Accountable Care Organizations: What Impact on Pharma?
|出版日||ページ情報||英文 50 Pages
|ACO：製薬会社に与える影響 Accountable Care Organizations: What Impact on Pharma?|
|出版日: 2015年07月16日||ページ情報: 英文 50 Pages||
ACO (Accountable Care Organization：患者に対して責任を持って治療を行う組織) は、米国における新しい医療制度のエンティティです。
The Affordable Care Act (ACA) passed in 2010 was the catalyst to a range of changes to the US healthcare system. Among the most important of these changes was how healthcare is paid for, with a number of ACA measures aimed at moving away from a fee-for-service reimbursement to payment of providers according to outcomes and quality of care. This shift from volume- to value-based reimbursement is captured most prominently in the establishment of Accountable Care Organizations (ACOs). ACOs are groups of doctors, hospitals, and other healthcare providers that share the risk, responsibility, and reward associated with delivering more cost-effective, higher-quality, and better-coordinated care. There are now over 700 ACOs in the US, spanning both the publicly funded Medicare and Medicaid, as well as the private sector.
The impact of this growing ACO movement on the pharma industry has so far been limited, but this is changing. Pharma firms have opportunities to engage with these restructured providers in new ways, including by helping to influence and set treatment best practice across different therapy areas, providing pharmacoeconomic and outcomes data, and potentially supporting a more prominent role for pharmacists within ACOs.
This report addresses the following questions: